Experimental CAR t cell cocktail takes on recurrent glioblastoma

NCT ID NCT04003649

Ongoing Disease control Sponsor: City of Hope Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests whether a special type of immune cell (CAR T cell) that targets a protein found on glioblastoma cells can be safely given along with two immunotherapy drugs (nivolumab and ipilimumab). The study involves 20 adults with recurrent or treatment-resistant glioblastoma. The main goals are to check for side effects and see if the treatment is feasible before and after surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IL13Rα2-targeted CAR T cells (a type of immune cell therapy) combined with nivolumab and ipilimumab (immunotherapy drugs)
What this could lead to: If successful, this could point toward a new treatment option for recurrent glioblastoma, a brain cancer with very few effective therapies.
What could go wrong: This is a very early (phase 1) and small trial (20 people), focused mainly on safety. The combination may cause serious side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma refractory malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT GLIOBLASTOMA REFRACTORY GLIOBLASTOMA

Contacts and locations

Locations

City of Hope Medical Center

Duarte, California, 91010, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.